



P R E S S R E L E A S E

Lelystad, the Netherlands, 4 January 2011

Divestment of German activities by Fornix

Fornix BioSciences N.V. (**Fornix**) announces that the divestment of Artu Biologicals Deutschland GmbH & Co. KG (**Artu Deutschland**) has been completed by the transfer of (i) the sole limited partner's interest in Artu Deutschland, and (ii) the entire issued share capital of Artu Biologicals Deutschland Verwaltungs GmbH, being the sole general partner of Artu Deutschland by Fornix to Rölke Pharma GmbH effective as of the end of 31 December 2010. The decision to divest Artu Deutschland is a consequence of Fornix's strategic review as published on 8 December 2010. All the liabilities of the loss making entity Artu Deutschland has been transferred and as a result no material consideration has been paid.

As a consequence of this transaction the expected net profit of Fornix on the financial year 2010 will be reduced by the book loss on Artu Deutschland by EUR 1.8 million to approximately EUR 18.2 million.

E N D O F P R E S S R E L E A S E

For additional information, please contact: Fornix BioSciences N.V.

C.L. Bergman, CEO

Tel. +31 (0) 320) 26 77 99

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) engaged in the distribution of medical aids and medical and nursing consumables. The company, which operates sites in Lelystad and Beuningen, currently employs approximately 20 people. Fornix BioSciences N.V. operates mainly in the Netherlands and is currently only engaged in the sale and distribution of medical aids.

The Medical Aids Division consists of Laprolan, which is located in Beuningen, and specialises in the sale, marketing and distribution in the Netherlands of a wide range of medical aids and medical and nursing consumables.